Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : SYNSORB (T.SYB)(SYBBF) CURE FOR CANCER? -- Ignore unavailable to you. Want to Upgrade?

To: Tupulak who wrote (49)	6/10/1999 8:56:00 AM
From: Tupulak	Respond to of 164

YNSORB Biotech Inc. Appoints New Director CALGARY, ALBERTA--SYNSORB Biotech Inc. today announced the appointment of Andre G. Pernet, Ph.D., formerly with Abbott Laboratories, to the Company's Board of Directors. Dr. Pernet most recently served as corporate officer and Vice President, Pharmaceutical Products Research and Development for Abbott Laboratories heading an organization of 2700 scientists with an annual budget responsibility of US$600 million. Among his accomplishments while at Abbott is the worldwide development of the antibiotic Biaxin (clarithromycin) the sales of which peaked at $1.2 billion. Dr. Pernet also spearheaded the AIDS research program at Abbott and developed Norvir, one of the three breakthrough protease inhibitors which together reduced mortality in AIDS patients by 74 percent. In February 1999, Pernet's team was awarded the Prix Galien International, which is considered the highest distinction for medical and scientific contribution. After 26 years of service, Dr. Pernet recently retired from Abbott Laboratories and is currently serving on the Board of Directors of Celeris Corporation and Stern Cell Pharmaceuticals, Inc. "Dr. Pernet brings a wealth of experience in pharmaceutical product development to our Board," said Dr. Brad Thompson, Executive Chairman of the Board in announcing the appointment. "His presence represents an important element in the future growth and success of SYNSORB." SYNSORB is dedicated to accelerated drug development from the acquisition of promising compounds emerging from basic research through clinical development, and ultimately to providing channels to market for new discoveries. Headquartered in Calgary, SYNSORB currently has two products in late stage clinical development, SYNSORB Pk(R) for the prevention of HUS and the treatment of verotoxigenic E. coli (VTEC) infections (including O157:H7), and SYNSORB Cd(R) designed to treat recurrent antibiotic-associated diarrhea (CDAD). SYNSORB has additional compounds in pre-clinical development, including REOSYN, a potential cancer treatment being developed within its subsidiary company, Oncolytics Biotech Inc., and novel antibiotics, with inflammation and anti-virals targeted in the Company's research and development program. Shares of SYNSORB Biotech Inc. trade on the Toronto Stock Exchange in Canada (symbol "SYB") and on NASDAQ in the United States (ticker "SYBB"). This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include results of current or pending clinical trials, actions by the FDA/HPB and those factors detailed in the Company's registration statement on Form 20 F filed with the Securities and Exchange Commission. -30- FOR FURTHER INFORMATION PLEASE CONTACT: The Equicom Group Jason Hogan Investor Relations (416) 815-0700 ex 222 (416) 815-0080 (FAX) jhogan@equicomgroup.com synsorb.com or SYNSORB Biotech Inc. Dr. Brad Thompson Executive Chairman of the Board (403) 283-5900 (403) 283-5907 (FAX) synsorb.com

To: Tupulak who wrote (49)	6/10/1999 8:58:00 AM
From: Tupulak	Read Replies (1) \| Respond to of 164

Canadian Company Press Release SYB 1999-06-10 (provided courtesy of Canadian Corporate News.) register to receive future releases by email from CCN SYNSORB Biotech Inc. Licenses Carbohydrate Compounds Targeting Cystic Fibrosis Treatment CALGARY, ALBERTA--SYNSORB Biotech Inc. ("SYNSORB") (TSE: SYB, NASDAQ: SYBB), a pharmaceutical development company, today announced that it has licensed technology for the treatment of lung complications associated with Cystic Fibrosis (CF) from a consortium including the Canadian Bacterial Disease Network (CBDN), the Canadian Microbiology Consortium Inc. (CMCI), The University of Alberta, the University of British Columbia, and Novadex Pharmaceuticals Limited. In animal model studies, the licensed compounds have demonstrated utility in both reducing the viscosity of mucous and inhibiting the proliferation of bacteria in the lungs of CF patients. Cystic Fibrosis is an inherited disorder that primarily affects the lungs and digestive tract, and for which there is no cure. It is the most common life-shortening genetic disease that affects the Caucasian population. In North America alone, approximately 33,000 patients suffer from the disorder, and approximately 1,100 new cases are diagnosed each year, usually by the age of three. CF leads to progressive functional disturbances in various organs, including the lungs, liver, pancreas, reproductive organs and joints resulting in an average life expectancy of 31 years. The basic defect in CF patients is the inability of cells which line organs such as the lungs and pancreas to effectively transport sodium and chloride (salt) to the outer surface of the cell for disposal. Its effects are most devastating in the lungs, where CF causes the body to produce an abnormally thick, sticky mucous which clogs the lungs and can lead to fatal infections. These infections are often caused by bacteria such as Pseudomonas aeruginosa and Burkholderia cepacia that are very resistant to current antibiotics. The respiratory problems that result from CF usually require patients to undergo rigorous daily treatment programs involving percussion, postural drainage and aerosol medications. The compounds licensed by SYNSORB are carbohydrate based. In animal model and other studies, the compounds have shown to be effective in the reduction of CF mucous thickness and thus will enhance the clearance from patients with CF. "These compounds are very well suited to SYNSORB's expertise in the area of carbohydrate drug development," said Dr. David Cox, President and CEO. "Consistent with our strategic direction, SYNSORB expects to finance the project through a third party off-sheet financing vehicle, and we are greatly looking forward to working with the research consortium on this project." The CBDN is part of the Networks of Centres of Excellence program, and is a Canada-wide consortium of 53 researchers and their laboratory personnel whose work focuses on bacterial disease. CBDN's mission is to advance scientific knowledge and enhance Canada's economic competitiveness through networking, excellence in fundamental research on bacterial diseases and collaboration with industry (putting fundamental science to work). CMCI is responsible for commercializing technologies resulting from the CBDN scientific network. SYNSORB is dedicated to accelerated drug development from the acquisition of promising compounds emerging from basic research through clinical development, and ultimately to providing channels to market for new discoveries. Headquartered in Calgary, SYNSORB currently has two products in late stage clinical development, SYNSORB Pk(R) for the prevention of HUS and the treatment of verotoxigenic E. coli (VTEC) infections (including O157:H7), and SYNSORB Cd(R) designed to treat recurrent antibiotic-associated diarrhea (CDAD). SYNSORB has additional compounds in pre-clinical development, including REOSYN, a potential cancer treatment being developed within its subsidiary company, Oncolytics Biotech Inc., and novel antibiotics, with inflammation and anti-virals targeted in the Company's research and development program. Shares of SYNSORB Biotech Inc. trade on the Toronto Stock Exchange in Canada (symbol "SYB") and on NASDAQ in the United States (ticker "SYBB"). This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include results of current or pending clinical trials, actions by the FDA/HPB and those factors detailed in the Company's registration statement on Form 20 F filed with the Securities and Exchange Commission. -30- FOR FURTHER INFORMATION PLEASE CONTACT: SYNSORB Biotech Inc. David Cox, Ph.D President and CEO (403) 283-5900 (403) 283-5907 (FAX) or The Equicom Group Jason Hogan Investor Relations (416) 815-0700 ex 222 (416) 815-0080 (FAX) or SYNSORB Biotech Inc. W. Douglas Froom Vice President, Business Development (403) 283-5900 (403) 283-5907 (FAX) synsorb.com For product licensing information